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Key Points 
 
• miR-18b overexpression identifies patients with poor prognosis in two large prospective 
MCL cohorts treated with Rituximab-chemo and ASCT 
• miR-18b overexpression adds prognostic information to the MIPI-B prognosticator 
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 Abstract 
Recent studies show that mantle cell lymphoma (MCL) express aberrant miRNA profiles, however, 
the clinical effect of miRNA expression has not previously been examined and validated in 
prospective, large, homogenously treated cohorts. We analyzed diagnostic MCL samples from the 
Nordic MCL2 and MCL3 clinical trials, in which all patients had received Rituximab-high-dose 
cytarabin alternating with Rituximab-maxiCHOP, followed by BEAM and autologous stem cell 
support. We performed genome-wide miRNA microarray profiling of 74 diagnostic MCL samples 
from the MCL2 trial (screening cohort). Differentially expressed miRNAs were re-analyzed by 
qRT-PCR. Prognostic miRNAs were validated by qRT-PCR in diagnostic MCL samples from 94 
patients of the independent MCL3 trial (validation cohort). 
 
Three miRNAs (miR-18b, miR-92a, miR-378d) were significantly differentially expressed in 
patients who died from MCL in both the screening- and the validation cohort. MiR-18b was 
superior to miR-92a and miR-378d in predicting high risk. Thus, we generated a new MIPI-B-miR 
prognosticator, combining expression-levels of miR-18b with MIPI-B data. This prognosticator 
improved identification of high risk patients compared to MIPI-B with regard to cause-specific 
survival (P=0.015), overall survival (P=0.006) and progression-free survival (P<0.001). 
Transfection of two MCL cell lines with miR-18b decreased their proliferation rate without 
inducing apoptosis, suggesting miR-18b may render MCL cells resistant to chemotherapy by 
decelerating cell proliferation.  
Thus, we conclude that overexpression of miR-18b identifies patients with poor prognosis in two 
large prospective MCL cohorts and adds prognostic information to MIPI-B. MiR-18b may reduce 
the proliferation rate of MCL cells as a mechanism of chemoresistance. 
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Introduction 
Mantle-Cell Lymphoma (MCL) is an aggressive B-cell lymphoma subtype characterized by the 
pathogenic hallmark, the t(11;14)(q13;q32) translocation, which leads to overexpression of the cell-
cycle promoting protein Cyclin D1.1 New treatment regimens, including CD20-antibodies, high 
dose chemotherapy and autologous stem cell support (ASCT), have improved survival 
exceptionally.2–4 Despite this, long-term follow up data from the Nordic MCL2 trial show that 57% 
of younger MCL patients (≤65 years) relapse during a 10-year period.5 Risk-stratification is 
therefore of great importance in order to identify patients who are eligible for novel or alternative 
treatment regimens. The current prognostic models, the clinical MCL International Prognostic 
Index (MIPI),6 and the biological MIPI (MIPI-B), which includes staining with the proliferation 
marker Ki-67, assign patients to high, intermediate, or low risk groups. This prognosticator has been 
investigated in several cohorts4,7–11 and was useful in most.7–10 The MIPI-B does not, however, 
identify specific biological pathways designating aggressive subtypes of MCL. 
MicroRNAs (miRNAs) are a class of non-coding RNAs that inhibit translation of 
specific messenger RNAs (mRNAs), and can function as both tumor suppressor miRNAs and 
oncogenic miRNAs depending on the cellular context.12 Because of their small size (19-22 
nucleotides), miRNAs are well preserved and can be successfully examined in formalin-fixed 
paraffin-embedded (FFPE) tissue, showing expression levels that correlate with those obtained in 
cryopreserved tissue.13 We have previously purified miRNAs from FFPE tissue in cutaneous T-cell 
lymphoma14 and diffuse large B-cell lymphoma,15 and obtained reproducible miRNA levels in 
samples stored for up to 30 years. 
Over the last five years, several studies have shown that miRNAs delineate aberrant 
molecular pathways and predict survival in MCL patients.16,17 Furthermore, the knockdown of 
specific miRNAs in two MCL-mouse models has demonstrated efficacy in inhibiting lymphoma 
growth.18,19 However, there has been only modest consistency between the clinical studies, and at 
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this point, miRNA expression in MCL has not yet been examined in large, prospective, uniformly 
treated patient cohorts.  
To identify aberrant biological pathways and find prognostic biomarkers, we 
examined miRNA expression levels in 168 MCL patients from the almost identical Nordic MCL2 
and MCL3 trial cohorts according to REMARK guidelines.20 All patients had been treated with 
high-dose immunochemotherapy and ASCT, and had long-term follow-up. We initially analyzed 
the genome-wide miRNA expression-profile of diagnostic patient samples in the Nordic MCL2 
cohort and linked these findings with comprehensive clinical follow-up data. Validation of 
differentially expressed miRNAs was performed in samples from patients in the Nordic MCL3 
cohort to determine the prognostic value of miRNA expression in MCL patients. Finally, the 
functional implications of aberrant miRNA expression were studied in MCL cell lines. 
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Methods 
Figure 1 provides a flowchart summarizing the experimental procedures.  
Study population 
All patients included in this study have been enrolled in two similar prospective trial cohorts; The 
2nd Nordic Lymphoma Group MCL Trial cohort (MCL2), or The 3rd Nordic Lymphoma Group 
MCL Trial cohort (MCL3). The study designs of the MCL2 and MCL3 trials have been published 
previously.2,21 Briefly, both cohorts consisted of newly diagnosed, previously untreated, stage II-IV 
MCL patients below the age of 66 years. All diagnostic specimens were centrally reviewed by at 
least one member of the central Nordic MCL Pathology board and the diagnosis confirmed 
according to World health Organization (WHO) criteria.22 All patients were followed with a 
complete work-up including clinical history, physical examination, blood and bone-marrow 
examination, and CT or PET-CT scans on study entry and subsequently every 6 months for 5 years. 
After 5 years, patients were followed with annual clinical assessment, standard blood tests, and 
minimal residual disease (MRD) analysis.23 
Both cohorts received the same treatment regimens consisting of rituximab(R)-maxi-
CHOP alternating with R-high-dose Ara-C, followed by high-dose BEAM or BEAC and ASCT. 
The only difference between the two regimens was that MCL3 patients with unconfirmed complete 
remission (CRu) or partial remission (PR) received 90Y-Ibritumomab-Tiuxetan	(Zevalin) in addition 
to BEAM or BEAC before ASCT. The addition of Zevalin did not have any impact on treatment 
outcome or adverse events, and overall survival, event-free survival, and time to progression were 
similar in the two cohorts.21 In both cohorts, a fraction of these patients also received pre-emptive 
Rituximab at molecular relapse during follow up.23 
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Patient samples 
A total of 172 FFPE preserved diagnostic MCL biopsies from 172 MCL patients from both cohorts 
(76 MCL2 and 96 MCL3, respectively) were retrieved from the respective Nordic MCL pathology 
board. Four patients were excluded due to poor quality of the RNA extracted from the MCL 
specimens. All included patient samples had confirmed overexpression of cyclin D1 or carried the 
t(11;14)(q13;q32) translocation. Ki-67 expression was evaluated by immunohistochemistry in 145 
patient samples, and a marker for MRD23 was available in 96 of these. 
The clinical trials (MCL2: ISRCTN 8786 6680, MCL3: NCT 00514475) were 
conducted in accordance with the Declaration of Helsinki, and approved by the relevant ethic 
committees of all Nordic countries. Informed consent was obtained from all participants. 
 
RNA extraction from FFPE-tissue  
Total RNA from all samples was isolated from four 10µm tissue sections using the RecoverAll total 
nucleic acid isolation kit (Ambion, Carlsbad, CA, USA) according to the manufacturer’s guidelines. 
The samples were incubated in Xylene at 50°C to remove paraffin, followed by ethanol wash. 
Proteins were degraded by digestion buffer and protease at 50/80°C. Subsequently, isolation buffer 
and ethanol were added, samples were bound to a spin-column, and DNA was degraded by DNAse 
treatment. The filter was washed and total RNA was eluted in a 60 µL elution solution. Total RNA 
quantity (OD 260 nm) and quality (260/280 ratio) were measured by an ND-1000 
spectrophotometer (Thermo Scientific, Delaware, USA). 
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miRNA microarray analysis 
For miRNA microarray profiling, 500 ng of total RNA from samples or reference (AM6000; 
common RNA pool for identifying a maximum number of expressed miRNAs in patient samples, 
Ambion, Carlsbad, CA, USA) was labeled with Hy3 and Hy5 fluorescent dyes, respectively, using 
the miRCURY LNA array power labeling kit (Exiqon A/S, Vedbæk, Denmark). Samples with RNA 
concentrations lower than 160 ng/µl were vacuum-centrifuged (speedvac) to obtain higher 
concentrations. All samples were labeled the same day with the same master mix to minimize 
technical variation. 
The labeled samples were hybridized to miRCURY LNA 7th generation arrays 
(Manual version 2.2; Exiqon A/S, Vedbæk, Denmark), containing capture probes targeting all 
human miRNAs registered in  miRBASE release 18.0 (1896 human miRNAs). The hybridization 
was performed overnight at 56°C according to the manufacturer’s specifications using an HS4800 
hybridization station (Tecan, Männendorf, Switzerland). Since it was not possible to hybridize all 
arrays at the same time point, samples were randomly split into six batches to minimize day-to-day 
variation in the hybridization process, and analyzed over six consecutive days. After hybridization, 
the microarray slides were scanned in an ozone free environment in order to prevent potential 
bleaching of the fluorescent Hy5 dye. Scanning was done using a G2565BA Microarray Scanner 
system (Agilent Technologies, Santa Clara, CA, USA) at 10-µm resolution, and the resulting TIFF 
images were analyzed using the GenePix 6.1 software on standard settings. 
Microarray data can be found in the Gene Expression Omnibus database 
(http://www.ncbi.nlm.gov/geo/) with accession GSEXXXX.  
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Microarray data processing  
Processed microarray image data (Genepix median spot intensities) were read into the R statistical 
environment and preprocessed using the LIMMA package.24 The arrays were background corrected 
using the 'normexp' method with an offset of 10 to account for spatial biases as suggested by 
Ritchie et al. (2007),25 and between-array variance was eliminated by quantile normalization.26,27 
Expression profiles and clinical variables were subjected principal component analysis (singular-
value decomposition) to assess whether data were affected by unexpected confounding effects.  
A differential expression analysis of the foreground intensities was conducted for the cause-specific 
death contrast. Empirical Bayes moderated statistics were assessed and adjusted for multiple testing 
using the Benjamini-Hochberg method. 
 
Quality assessment of patient samples 
Principal components analysis of miRNA microarray data and sample related parameters 
(anatomical site of origin of MCL-biopsy, country, batch, speedvac-procedure, cytology or growth 
pattern) confirmed that none of these factors had any influence on the quality of the microarray data 
(data not shown).  
 
miRNA qRT-PCR 
Ten ng of RNA were reverse transcribed in 10µL reactions using miRCURY LNA Universal RT 
miRNA PCR, polyadenylation, and cDNA synthesis kit (Exiqon A/S). cDNA was diluted 40 times 
and assayed in duplicate 10µL PCR reactions according to protocol. Negative controls excluding 
template from the reverse transcription reaction were performed and profiled in parallel. The qRT-
PCR reactions were performed on a LightCycler II instrument (Roche, Basel, Switzerland) in 96- 
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and 384-well plates. The amplification curves were analyzed using Roche LightCycler version 
1.5.1.62 software, both for determination of crossing point (Cp, by the second derivative method) 
and for melting curve analysis. All assays were inspected for distinct and uniform melting curves to 
verify that the correct amplicon was amplified in all samples. Furthermore, samples were only 
included in the data analysis if their Cp-value was 3 less than the negative control, and with Cp < 
39. Samples that did not pass these criteria were omitted from further analysis. To eliminate bias of 
miRNA concentrations due to differences in initial RNA concentration, data were normalized using 
averaging windows (LOESS method). MiR-500a-5p, miR-335-3p and miR-423-5p had lowest 
variance among expressed miRNAs on the microarray, which were confirmed by qPCR, and were 
selected as reference miRNAs. 
Statistics and response criteria 
Differences in baseline characteristics between the two cohorts were calculated using the Pearson 
chi-squared test and Mann-Whitney non-parametric test. Outcome-related variables were assessed 
with Kaplan-Meier analyses and compared using the log-rank test. The prognostic information of 
the miRNAs was evaluated using the minimal-redundancy-maximal-relevance (mRMR) 
criterion.26,27 Comparison of the MIPI-B prognosticator and the MIPI-B-miR prognosticator was 
performed with respect to the prediction of high risk-groups. Statistical analyses were performed 
using SPSS version 20.0.0 (IBM, NY) and R version 2.1.4 (www.r-project.org). Two-sided tests 
with a significance level of 5% were used for all analyses.  
The prospective nature of the two MCL trials enabled us to use cause-specific survival 
(CSS) as primary endpoint according to response criteria of the International Workshop.28 
Progression-free survival (PFS) and overall survival (OS) were used as secondary endpoints. 
Multivariate Cox regression analysis was performed with backward selection to assess prognostic 
factors.  
 
Cell culture 
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The MCL cell line, Z-138, was obtained from ATCC whereas Jeko-1 was provided by the European 
MCL Network. The cells were maintained as suspension cultures in either RPMI (Jeko-1) or IMDM 
(Z-138) supplemented with 20% heat inactivated fetal calf serum (FCS), 10 U/mL penicillin, and 10 
µg/mL streptomycin. All tissue culture reagents were purchased from Life Technologies. The cells 
were maintained in a humidified chamber with 5% CO2 at 37°C. 
 
Electroporation 
Jeko-1 and Z-138 cells were transfected in a Nucleofector II device (Lonza) using program X-001. 
Briefly, 5 × 106 cells were resuspended in 100 µl Solution V (Lonza) containing 1 µM of either 
miR-18b mirVana miRNA mimic (Life Technologies) or a scrambled negative control mirVana 
miRNA mimic (Life Technologies). Immediately after electroporation, the cells were transferred to 
pre-heated complete medium and incubated at 37°C until further analysis by Flow Cytometry 
(FACScalibur, Becton Dickinson) or XTT assay. 
 
Apoptosis and cell proliferation/viability assays 
Apoptosis was assessed using the Annexin V-PE/7-AAD apoptosis detection kit (BD Biosciences), 
according to the manufacturer’s protocol. Briefly, 24 hours after transfection 1 × 106 cells were 
incubated with 5 µl Annexin V-PE and 5µl 7-AAD in 100 µl of 1 × Annexin V-binding buffer at 
room temperature. After incubating for 15 min, 400 µl of 1 × binding buffer was added, and the 
apoptotic cells were then analyzed by Flow Cytometry.  
To study cell proliferation, Jeko-1 and Z-138 cells were seeded in 96-well plates 
immediately after transfection at a density of 5-10 × 104 cells/well in 50 or 100 µl complete 
medium, respectively. Cell number was determined 0-7 days after transfection by adding 25 or 50 
µl 2,3-bis[2-methoxy- 4-nitro-sulfophenyl]-2H-tetrazolium-5-carboxanilide inner salt (XTT; Roche 
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Diagnostics) reagent to each well and measuring the absorbance at 450 nm (reference 650 nm) after 
3h of incubation at 37°C.   
 
.  
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Results  
Clinical characteristics of the study cohorts 
Baseline characteristics of MCL2 and MCL3 patients were similar with respect to gender, initial 
duration of response, WHO performance status, white blood cell count (WBC), lactate 
dehydrogenase (LDH), age, Ki67 expression and MIPI score, but differed significantly with regard 
to cytological variant. Follow-up was complete for all patients of both cohorts, with a median 
follow-up time of 6.4 years and 3.7 years, respectively (supplemental Table 1).  
 
miRNA microarray screening of the MCL2 cohort reveals 17 differentially expressed miRNAs in 
patients who die from MCL 
We initially assessed the global miRNA profile of 74 diagnostic samples from patients of the MCL2 
cohort by miRNA microarray. To identify prognostic miRNAs in MCL, each microarray was 
subjected to a statistical hypothesis test (see Methods) with regard to the CSS. This endpoint was 
chosen to evaluate the impact of the specific biological (miRNA) aberrations, and was possible 
because of the extensive follow-up in the two clinical trials. Seventeen miRNAs were found to be 
differentially expressed (adjusted p-values < 0.05; see Table 1), with 14 miRNAs being up-
regulated and 3 miRNAs being down-regulated in patients who died from MCL. A heatmap of the 
differentially expressed miRNAs is shown in Figure 2.  
 
qRT-PCR confirms miRNA microarray findings in the MCL2 cohort  
To confirm the microarray findings we chose 26 miRNAs to be analyzed by qRT-PCR in the same 
74 MCL2 patient samples: Seventeen miRNAs were selected on the basis of adjusted p-values < 
0.05 on the microarray (Table 1), and two miRNAs were selected on the basis of combined adjusted 
p-values < 0.1 and differential expression in previous MCL studies (miR-146a-5p, miR-92a-3p).18,29 
Four additional miRNAs (miR-29a, miR-29b, miR-29c and miR-20b), also known from the 
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literature,30,31 but not differentially expressed in our microarray analysis, were also chosen for qRT-
PCR analysis in MCL2. Three miRNAs were selected as reference miRNAs on the basis of their 
low variance of expression across all microarrays (supplemental Figure 1). 
With regard to CSS, seven of the miRNAs selected for qRT-PCR analysis (miR-4417, 
miR-18b-5p, miR-3687, miR-378d, miR-185-5p, miR-144-3p, and miR-92a-3p) were differentially 
expressed thus confirming the microarray findings in the MCL2 cohort (Table 1). Log fold changes 
tended to be higher in the qRT-PCR analysis compared to the microarray, and the adjusted p-values 
were correspondingly lower by qRT-PCR than by microarray.  
 
High expression of miR-18b predicts poor prognosis in MCL 
Previous studies have identified various miRNAs that predict outcome in heterogeneous cohorts of 
MCL patients,16,17 however, the prognostic value of miRNA profiles in similarly treated cohorts of 
MCL patients remains to be demonstrated. To evaluate the prognostic performance of the 
differentially expressed miRNAs we performed mRMR analysis and a leave-one-out cross-
validation using linear discriminant analysis (LDA). The maximum enhancement of the prognostic 
accuracy of MIPI-B was achieved by miR-18b expression (supplemental Figure 2), and, in addition, 
a univariate analysis revealed that miR-18b overexpression was significantly correlated with poor 
survival in MCL2 (P < 0.001, log-rank) (supplemental Figure 3).  
 
Validation in the independent MCL3 cohort 
In order to validate findings from the MCL2 cohort, we analyzed the confirmed differentially 
expressed miRNAs in the independent, but similarly treated, MCL3 cohort by qRT-PCR. Here we 
were able to validate miR-18b, miR-378d and miR-92a as being significantly overexpressed 
(adjusted P<0.05) in patients who died from MCL (Table 1). Both miR-18b and miR-92a have 
previously been associated with aggressive subtypes of MCL, whereas miR-378d is a novel 
prognostic factor for survival in MCL. 
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MIPI-B-miR: Addition of miR-18b expression improves the prognostic value of MIPI-B 
Several studies, including the Nordic MCL2 trial,7 have confirmed the MIPI-B score as the best 
performing prognosticator of MCL outcome. In order to assess the prognostic value of miRNA 
expression, we incorporated the MIPI-B components with expression data of miR-18b. Based on 
the MCL2 screening cohort, we developed a novel prognostic index using LDA of miR-18b 
expression levels and MIPI-B value to assign patients to high, intermediate or low risk. This new 
prognostic index, MIPI-B-miR, was defined as: 𝜔! = 𝜔 + 𝑐𝑥, where 𝜔 is the MIPI-B value, x is the 
log-fold-change of miR-18b, and c is a regression parameter (c=0.58317). The low risk was defined 
as 𝜔! < 5.75, high risk was defined as 𝜔! > 7.49 and intermediate risk is implied when MIPI-B-
miR values fall between these thresholds (supplemental text).  
   MIPI-B-miR had a significantly better separation of patients in low, intermediate and 
high risk groups compared to the standard MIPI-B regarding overall survival (OS) and progression-
free survival (PFS), and was borderline significant with regard to CSS (Figure 3A-C). In particular, 
the MIPI-B-miR reduced the number of high-risk patients by two thirds, and identified a group of 
patients with an exceedingly poor outcome compared to that identified by the MIPI-B high-risk 
index.  
To confirm these findings we blindly tested the MIPI-B-miR prognosticator on the 
independent MCL3 validation cohort. The MIPI-B-miR also improved the separation of risk groups 
in the validation cohort regarding CSS, OS and PFS (Figure 4 A-C), e.g. MIPI-B-miR achieved 
significant prognostic value for OS (P<0.001), while MIPI-B does not (P=0.143). Compared to 
MIPI-B, MIPI-B-miR showed a trend of improved identification of high risk patients (CSS: 
P=0.101, OS: P=0.101 and PFS: P=0.097), despite the shorter observation time in this cohort.  
Based on the improved prognostication by MIPI-B-miR, we next applied this index to 
the entire patient material (MCL2 and MCL3). In the combined analysis MIPI-B-miR was superior 
to the standard MIPI-B at identifying high risk patients with respect to CSS, OS and PFS (Figure 5 
A-C and supplemental Figure 4). In the subset of patients with a known MRD marker, MIPI-B-miR 
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predicted a high risk of molecular relapse (P<0.001), while MIPI-B did not (P=0.322; supplemental 
Figure 5). Importantly, MIPI-B-miR was still significantly superior to MIPI-B at predicting CSS 
(P=0.034), OS (P=0.034) and PFS (P=0.006) when patients receiving pre-emptive Rituximab were 
excluded from the analysis of the combined cohort (MCL2 and MCL3) (supplemental Figure 6). 
Finally, a multivariate analysis of the combined MCL2 and MCL3 cohorts confirmed miR-18b as 
an independent prognostic factor for OS (supplemental Table 3).  
 
MiR-18b function 
 
To investigate the possible functional consequences of miR-18b overexpression, two MCL cell 
lines, Z-138 and Jeko-1, were selected due to their high transfection efficiency. Both cell lines 
express miR-18b at intermediate levels compared with primary MCLs expressing high or low levels 
of miR-18b (Figure 6 A). Z-138 and Jeko-1 cells transfected with miR-18b mimic display 
significantly lower viability scores compared to cells transfected with scrambled miRNA as 
measured by XTT assay (P=0.05 and P=0.005, respectively) (Figure 6 B). The low cell viability 
observed upon miR-18b overexpression was not associated with the induction of apoptosis, as no 
increase in the early apoptotic cell population was detected when miR-18b transfected cells were 
compared to scrambled miRNA transfected cells (Figure 6 C). However, when comparing the 
proliferation rate between cells transfected with miR-18b or scrambled miRNA, miR-18b was 
found to markedly inhibit the proliferative ability of both Z-138 and Jeko-1 cells over an 8-day test 
period although this was most pronounced in Jeko-1 cells (Figure 6 D). Overexpression of miR-18b 
in Jeko-1 and Z-138 cells did not alter their cell cycle profile, when compared to scrambled miRNA 
transfected cells (data not shown), indicating miR-18b likely inhibits cell cycle progression at 
multiple points.  
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Discussion 
 
This study of 168 patients provides the most comprehensive study of miRNA expression profiles in 
MCL to date. Moreover, it is the first study to prospectively follow and analyze miRNA expression 
in a large, homogeneously treated cohort of MCL patients. The detailed trial data also enabled us to 
study CSS, excluding treatment-related deaths or deaths from other causes. By analyzing the 
expression of 1896 human miRNAs by microarray in patients from the MCL2 cohort, we identified 
17 miRNAs that were significantly up- or down-regulated in patients who died from MCL. qRT-
PCR analysis confirmed that seven of these were up-regulated. Subsequent validation in the 
independent MCL3 cohort identified an aggressive MCL subtype, biologically characterized by 
aberrant overexpression of miR-18b, miR-92a and miR-378d. These miRNAs, and miR-18b in 
particular, signify MCL patients that are incurable by the current standard therapy R-maxi-
CHOP/R-high-dose Ara-C and BEAM/-C and ASCT. 
 
The prognostic impact of miRNAs have previously been studied in MCL, but mainly in smaller, 
heterogeneous cohorts, treated by variant regimens16,17 These studies have suggested a number of 
prognostic miRNAs including miR-18b,29 and the entire miR-17~92a cluster. However, no other 
study identified miR-92a as a key component. Here, we confirm that these miRNAs are valid 
prognostic markers in our large cohort of homogeneously treated MCL patients. Moreover, we 
observed that other previously published prognostic miRNAs (miR-146a, miR-20b, miR-29a, miR-
29c)29–31 displayed trends in our data that agreed with earlier findings, but were not statistically 
significant in this study. 
From a genomic perspective, miR-18b and miR-92a are located in two paralogue clusters (the miR-
106a~363 cluster on chromosome X and the miR-17~92a cluster on chromosome 13, respectively) 
with shared evolutionary origin.32 In particular, overexpression of the miR-17~92a cluster has been 
widely studied, and has been implicated in both benign and malignant lymphoproliferative 
diseases,33 whereas the functions of the miRNAs in the miR-106a~363 cluster, which share 
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numerous seed sequences with the 17~92a cluster miRNAs, are less well explored.34 
Overexpression of miR-378d has been associated with poor prognosis in acute myeloid leukemia,35 
and with brain metastasis in non-small cell lung cancer,36 but has to our knowledge not been 
implicated in lymphoid malignancies. 
Although aberrantly expressed miRNAs have been suggested as prognostic markers 
for survival in MCL, no study has yet identified miRNAs that could improve upon the state-of-the-
art prognosticator, the MIPI-B.16,17 In the current study of two similar MCL trial cohorts, we find 
that the miR-18b expression level significantly adds prognostic information to the MIPI-B 
approach. By generating a new prognosticator, the MIPI-B-miR, we were able to predict survival of 
MCL patients after high-dose immunochemotherapy and ASCT and improve the gold standard 
prognosticator MIPI-B. Since the MIPI-B-miR was validated in a similarly treated cohort, and was 
also found to be significant in the whole test group, we believe this prognosticator may also have 
prognostic power in other cohorts of younger MCL patients treated by current standards (R-chemo-
ASCT). In addition, MIPI-B-miR was superior to MIPI-B in predicting molecular relapse. Because 
exclusion of cases treated with pre-emptive Rituximab did not change the overall picture, the MIPI-
B-miR may also be valid in settings without MRD surveillance and pre-emptive therapy. Future 
investigations using MIPI-B-miR will be required to demonstrate its validity in differently treated 
and elderly cohorts of MCL patients. In this study, quantification of miRNAs was performed by 
standard primer-based qRT-PCR on RNA extracted from FFPE preserved MCL-specimens, which 
are easily storable and accessible, emphasizing the feasibility and the robustness of the method.  
Beyond their value as prognostic markers, aberrantly expressed miRNAs may be 
therapeutic targets in patients,37 potentially enabling new therapies in the poor prognosis group. 
Unfortunately, the direct functions of these upregulated miRNAs in MCL are largely unknown. In 
particular divergent roles of miR-18b in carcinogenesis have been reported and complicate 
therapeutic approaches. For example, low expression of miR-18b has been shown to predict 
melanoma progression and short survival,38 whereas in hepatocellular carcinoma, high miR-18b 
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expression correlates with low survival rate.39   This is not surprising considering that different 
functions have been previously attributed to individual miRNAs in different cellular settings,12 and 
interestingly, high expression of miR-18b is characteristic of  human embryonic stem cells.40  
We have investigated miR-18b function in two MCL cell lines and observed that miR-18b 
overexpression significantly down regulated MCL cell proliferation. This observation supports that 
miR-18b adds prognostic information to MIPI-B by identifying an additional group of patients with 
poor prognosis, not identified by MIPI-B, which includes the proliferation marker Ki-67. The 
regimens used in the Nordic MCL2 and MCL3 trials comprise several cell cycle specific drugs 
including cytarabine, which will only target proliferating cells. Our in vitro studies clearly show an 
association between high miR-18b expression and low proliferation rate. We therefore suggest that 
high miR-18b expression may render MCL cells resistant to the MCL2/3 therapeutic regimens 
leading to poor prognosis. Inhibition of cell proliferation by miRNAs has previously been shown to 
play a pivotal role in chemoresistance, e.g. in osteosarcoma and colon cancer cells where both miR-
140 and miR-215 cause chemoresistance by reducing the proliferation rate.41,42  Since high 
expression of miR-18b is also typical of undifferentiated cells and embryonal carcinoma cells,40,43 it 
is tempting to speculate if miR-18b expression can induce stemness in MCL, which is a subject for 
further studies. 
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Tables 
Table 1 
Significantly, differentially expressed miRNAs according to cause-specific survival  
		 MCL2	(screening)	 MCL3	(validation)	
	
Microarray	 qPCR	 qPCR	
miRNA	 adj.	p-value	 adj.	p-value	 adj.	p-value	
hsa-miR-124-5p	 0,0002	 -	 -	
hsa-miR-4417	 0,0002	 0,02	 0,2309	
hsa-miR-18b-5p	 0,0004	 0,02	 0,0002	
hsa-miR-3687	 0,0046	 0,01	 0,1722	
hsa-miR-519d	 0,0046	 -	 -	
hsa-miR-378d	 0,0092	 0,02	 0,0137	
hsa-miR-144-3p	 0,0173	 0,03	 0,142	
hsa-miR-486-5p	 0,0173	 0,05	 0,0644	
hsa-miR-1915-5p	 0,0176	 -	 -	
hsa-miR-665	 0,0259	 -	 -	
hsa-miR-185-5p	 0,0308	 0,04	 0,059	
hsa-miR-4694-5p	 0,0405	 -	 -	
hsa-miR-5003-5p	 0,0427	 -	 -	
hsa-miR-301a-3p	 0,0439	 0,43	 -	
hsa-miR-3182	 0,0439	 -	 -	
hsa-miR-3591-3p	 0,0463	 -	 -	
hsa-miR-451a	 0,0496	 0,05	 0,4075	
hsa-miR-92a-3p	 0,0842	 0,04	 0,005	
hsa-miR-146a-5p	 0,0997	 0,16	 0,6801	
 
Hsa, homosapiens; adj, adjusted; minus sign (-) analysis was not performed. The miRNAs in bold 
are significantly differently expressed in both the screening cohort and the validation cohort. The 
miRNAs in italics are down-regulated in patients who die from MCL, miRNAs in normal typeface 
are up-regulated in patients who die from MCL 
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Legends to Figures 
Figure 1 
Flowchart of study 
A dual-method approach consisting of an initial screening by genome-wide miRNA-microarray of 
MCL samples from the MCL2 cohort, with subsequent confirmation of differentially expressed 
miRNAs by quantitative real time PCR (qRT-PCR) in the same patients. Confirmed differentially 
expressed miRNAs identified in the MCL2 cohort were validated by qRT-PCR in samples from the 
MCL3 cohort. 
 
Figure 2 
Heatmap of miRNAs differentially expressed in patients who die from MCL  
Hierarchical clustering of MCL samples from patients of the MCL2 cohort. The microarray 
generated heatmap demonstrates differentially expressed miRNAs (adjusted p-value <0.05) in 
patients who died from MCL (cause-specific death) compared to patients who did not die from 
MCL. 17 miRNAs were found to be differentially expressed; Of these, the 14 miRNAs shown at the 
top part of the figure had higher expression in the patients who died from MCL, while the three 
miRNAs shown in the bottom part had lower expression in the patients who died from MCL. 
 
Figure 3 
Outcome of MCL patients in the screening cohort (MCL2) according to MIPI-B and MIPI-B-
miRNA prognostic models 
The MIPI-B prognosticator (red) divides the cohort into three risk-groups according to established 
cut-off values. The MIPI-B-miR prognosticator (black), which also includes the qRT-PCR 
expression level of miR-18b, also divides the cohort into three risk-groups. Kaplan-Meier estimates 
of (A) cause-specific survival, (B) overall survival and (C) progression-free survival.  
 
 27 
 
Figure 4 
 
Outcome of MCL patients in the validation cohort (MCL3) according to MIPI-B and MIPI-B-
miRNA prognostic models	
	Kaplan-Meier estimates of (A) cause-specific survival, (B) overall survival and (C) progression-
free survival. 
 
Figure 5 
 
Outcome of MCL patients in a combined, similarly treated cohort (MCL2 and MCL2) 
according to MIPI-B and MIPI-B-miR prognostic models	
	
Kaplan-Meier estimates of (A) cause-specific survival, (B) overall survival and (C) progression-free 
survival.		
	
Figure 6 
MiR-18b inhibits cell proliferation in Jeko-1 and Z-138 cells lines. (A) Relative expression levels of 
miR-18b in Z-138, Jeko-1 compared to patient MCL samples (PTS) expressing high (PTS High) or 
low (PTS Low) miR-18b. Results are expressed as means +/- SD. (B) Cells were transfected with 1 
uM scrambled (Scr.) miRNA control or miR-18b mimic for 6 days after which cell numbers were 
determined by XTT assay. Results are expressed as means +/- SD. Statistical analyzes were 
performed using Student’s t-test. The significance level was set at 0.05. (C) Apoptosis was studied 
by flow cytometry in Annexin V-PE/7 AAD stained cells 24h after transfection with Scr. miRNA 
control or miR-18b mimic. (D) Growth curves for Z-138 and Jeko-1 transfected cells. Cell number 
was determined 0-8 days after transfection using XTT assay. Results are expressed as means +/- 
SD. 
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